

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/050246

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/704 A61P35/00 A61K31/282

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 03/082267 A (TURSI JENNIFER MARGARET ; FOWST CAMILLA (IT); GERONI MARIA CRISTINA RO) 9 October 2003 (2003-10-09) page 1, paragraph 1 page 4, paragraph 3 - page 4, line 21	1-15
X	"The combination of nemorubicin with cisplatin and mitomycin C is synergistic in experimental tumor models" November 2002 (2002-11), EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, PAGE(S) S20 , XP004403486 ISSN: 0959-8049 abstract	1-18

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

20 July 2004

Date of mailing of the international search report

05/08/2004

Name and mailing address of the ISA

Authorized officer

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/050251

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/704

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/38730 A (MASFERRER JAIME L ; GORDON GARY (US); SEARLE & CO (US); KOKI ALANE T () 6 July 2000 (2000-07-06) especially compound C-9 page 47 page 62, line 10 - line 11 page 75, line 3 - page 76, line 19 table 20 ----- -/-	1-45

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

14 July 2004

Date of mailing of the international search report

28/07/2004

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk

Authorized officer

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/EP2004/050246

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KABUTO M ET AL: "'Antitumor effect of MX2, a new morpholino anthracycline against C6 glioma cells and its combination effect with photodynamic therapy in vitro!" October 1995 (1995-10), NO TO SHINKEI. BRAIN AND NERVE. OCT 1995, VOL. 47, NR. 10, PAGE(S) 969 - 973 , XP009033767 ISSN: 0006-8969 abstract	1-3,6-15
X	"Preclinical activity against liver metastases of Nemorubicin, a DNA-intercalating cytotoxic agent for the treatment of hepatocellular carcinoma" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 38, November 2002 (2002-11), page S19, XP004403483 ISSN: 0959-8049 abstract	1-14
X	"Properties of the new anthracycline derivative containing modified daunosamine moiety" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 38, November 2002 (2002-11), pages S19-S20, XP004403485 ISSN: 0959-8049 abstract	1-15
X	US 4 672 057 A (BARGIOTTI ALBERTO ET AL) 9 June 1987 (1987-06-09) cited in the application the whole document	1-15
X	US 4 710 564 A (MIZOBUCHI SHIGEYUKI ET AL) 1 December 1987 (1987-12-01) cited in the application the whole document	1-15
X	GB 2 315 067 A (PHARMACIA SPA ; PHARMACIA & UPJOHN SPA (IT)) 21 January 1998 (1998-01-21) cited in the application the whole document	1-15
X	GB 2 296 495 A (PHARMACIA SPA ; ERBA CARLO SPA (IT)) 3 July 1996 (1996-07-03) cited in the application the whole document	1-15

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/050246

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>BONNER J A ET AL: "Doxorubicin decreases the repair of radiation-induced DNA damage"</p> <p>1990, INTERNATIONAL JOURNAL OF RADIATION BIOLOGY 1990 UNITED KINGDOM, VOL. 57, NR. 1, PAGE(S) 55-64 , XP009033771</p> <p>ISSN: 0020-7616</p> <p>abstract</p>	1-15
Y	<p>BONNER J A ET AL: "DOXORUBICIN ENHANCES RADIATION-INDUCED DNA DAMAGE"</p> <p>INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY, BIOLOGY, PHYSICS, vol. 15, no. SUPPL. 1, 1988, page 163, XP009033770</p> <p>& 30TH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY, NEW ORLEANS, LOU</p> <p>ISSN: 0360-3016</p> <p>abstract</p>	1-15
Y	<p>WU LI-TEH: "Doxorubicin as radiation potentiator: Concurrent doxorubicin and radiation therapy interaction and its clinical applications"</p> <p>INFUSION CHEMOTHERAPY: IRRADIATION INTERACTIONS: PRINCIPLES AND APPLICATIONS TO ORGAN SALVAGE AND PREVENTION OF SECOND PRIMARY NEOPLASMS ELSEVIER SCIENCE PUBLISHERS B.V., PO BOX 211, SARA BURGERHARTSTRAAT 25, 1000 AE AMSTERDAM, THE NETHERLANDS; ELSEV, 1998, pages 147-151, XP002289046</p> <p>ISSN: 0-444-82608-4</p> <p>the whole document</p>	1-15
Y	<p>JAGETIA GANESH CHANDRA ET AL: "Effect of doxorubicin on cell survival and micronuclei formation in HeLa cells exposed to different doses of gamma-radiation"</p> <p>STRAHLENTHERAPIE UND ONKOLOGIE, vol. 176; no. 9, September 2000 (2000-09), pages 422-428, XP002289047</p> <p>ISSN: 0179-7158</p> <p>abstract</p>	1-15
Y	<p>CHENOUIFI NORCHEN ET AL: "In vitro demonstration of synergy between radionuclide and chemotherapy"</p> <p>JOURNAL OF NUCLEAR MEDICINE, vol. 39, no. 5, May 1998 (1998-05), pages 900-903, XP009033769</p> <p>ISSN: 0161-5505</p> <p>abstract</p>	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/050246

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03082267	A	09-10-2003	WO 03082267 A1	09-10-2003
US 4672057	A	09-06-1987	GB 2172594 A	24-09-1986
			BE 904431 A1	16-07-1986
			BG 60535 B2	28-07-1995
			BR 1100255 A3	02-04-2002
			CZ 9104195 A3	17-03-1993
			DE 3609052 A1	25-09-1986
			HK 37392 A	04-06-1992
			JP 1791944 C	14-10-1993
			JP 4082160 B	25-12-1992
			JP 61221194 A	01-10-1986
			MX 9203114 A1	01-07-1992
US 4710564	A	01-12-1987	JP 1049357 B	24-10-1989
			JP 1564850 C	25-06-1990
			JP 61167696 A	29-07-1986
			JP 62016495 A	24-01-1987
			AT 49412 T	15-01-1990
			CA 1292225 C	19-11-1991
			DE 3668173 D1	15-02-1990
			EP 0188293 A1	23-07-1986
GB 2315067	A	21-01-1998	DE 69710573 D1	28-03-2002
			DE 69710573 T2	31-10-2002
			WO 9802446 A1	22-01-1998
			EP 0889898 A1	13-01-1999
			JP 11513040 T	09-11-1999
GB 2296495	A	03-07-1996	DE 19547958 A1	27-06-1996
			IT MI952614 A1	24-06-1996
			JP 8231581 A	10-09-1996